Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.53USD
19 Dec 2014
Price Change (% chg)

$-0.05 (-1.94%)
Prev Close
$2.58
Open
$2.57
Day's High
$2.64
Day's Low
$2.52
Volume
473,437
Avg. Vol
547,660
52-wk High
$8.42
52-wk Low
$1.00

SNSS.OQ

Chart for SNSS.OQ

About

Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a... (more)

Overall

Beta: 2.38
Market Cap (Mil.): $156.73
Shares Outstanding (Mil.): 61.95
Dividend: --
Yield (%): --

Financials

  SNSS.OQ Industry Sector
P/E (TTM): -- 180.08 38.03
EPS (TTM): -0.84 -- --
ROI: -489.32 -0.62 18.26
ROE: -- -1.77 19.16
Search Stocks

Sunesis slumps after cancer drug fails late-stage trial

- Sunesis Pharmaceuticals Inc said its experimental cancer drug did not meet the main goal in a late-stage trial, sending the company's shares plunging 77 percent to their lowest in more than two years.

06 Oct 2014

Sunesis slumps after cancer drug fails late-stage trial

- Sunesis Pharmaceuticals Inc said its experimental cancer drug did not meet the main goal in a late-stage trial, sending the company's shares plunging 77 percent to their lowest in more than two years.

06 Oct 2014

UPDATE 2-Sunesis slumps after cancer drug fails late-stage trial

(Adds conference call, analysts comments and updates share movement)

06 Oct 2014

CORRECTED-UPDATE 1-Sunesis stock slumps after cancer drug fails late-stage trial

(Corrects to drop phrase "main goal of the study" in paragraph six)

06 Oct 2014

US STOCKS-Small biotech stocks plummet in premarket

NEW YORK, Oct 6 - Sunesis Pharmaceuticals and Alcobra Ltd were both sharply lower in premarket trading on Monday, with both names tumbling on heavy volume after reporting the results of late-stage drug trials.

06 Oct 2014

Sunesis's cancer drug fails late-stage trial

Oct 6 - Sunesis Pharmaceuticals said its experimental cancer drug did not meet its main goal in a late-stage trial in patients with refractory acute myeloid leukemia, a type of bone marrow cancer.

06 Oct 2014

Competitors

  Price Change
Eisai Co., Ltd (4523.T) ¥4,680 +109.00
Johnson & Johnson (JNJ.N) $105.55 -1.26
Novartis AG (NOVN.VX) CHF93.05 +0.95
Pfizer Inc. (PFE.N) $31.94 -0.03
Merck & Co., Inc. (MRK.N) $59.58 +0.60
Celgene Corporation (CELG.OQ) $117.18 +0.70

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks